A region containing the variants of interest in
IFT172 was directly amplified from genomic DNA using TaKaRa
LA Taq DNA Polymerase with
10x LA PCR Buffer II (TaKaRa, Mountain View, CA) with a two-step PCR protocol (primers,
S2 Table). Initial denaturation at 94°C for 1min was followed by 30 cycles of 98°C for 10s denaturation and 64.1°C for 22min and 30s elongation. Final elongation was performed by incubation at 72°C for 10min. Product length was 22,800 bp. LR-PCR products were purified using
SPRI magnetic beads (Beckman Coulter Life Sciences, Brea, CA) according to the manufacturer’s protocol, with 2μl used for Qubit 2.0 Fluorometric Quantitation (Beckman Coulter Life Sciences) dsDNA high sensitivity assay. Purified samples were sequenced by Pacific Biosciences Sequel system (PacBio, Menlo Park, CA) according to manufacturer’s protocol using
SMRTbell Express Template Kit 2.0 and
Sequel Sequencing Kit 3.0. To obtain highly accurate reads, Circular Consensus Sequence (CCS) analysis was performed using Pacific Biosciences
SMRT Link (v6.0). CCS reads were aligned to human reference genome (hg19) using Minimap2 v. 2.24 [15 (
link)], sorted with SAMtools and visualized in IGV browser.
Neřoldová M., Ciara E., Slatinská J., Fraňková S., Lišková P., Kotalová R., Globinovská J., Šafaříková M., Pfeiferová L., Zůnová H., Mrázová L., Stránecký V., Vrbacká A., Fabián O., Sticová E., Skanderová D., Šperl J., Kalousová M., Zima T., Macek M., Pawlowska J., Knisely A.S., Kmoch S, & Jirsa M. (2023). Exome sequencing reveals IFT172 variants in patients with non-syndromic cholestatic liver disease. PLOS ONE, 18(7), e0288907.